[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100598121":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":44,"collaborators":20,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":50,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":20,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":70,"overallStatus":73,"whyStopped":20,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Shanghai MicroPort EP MedTech Co., Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Clinical study on the safety and efficacy ofFireMagic™ Magbot Ablation Catheter for rapid arrhythmia","EXPERIMENTAL","Multicentre, target value method, single-arm",[13],"Device: FireMagic™ Magbot Ablation Catheter",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","FireMagic™ Magbot Ablation Catheter","All patients signed informed consent forms, enrolled in the trial, underwent surgical treatment for rapid arrhythmia using XX, and were discharged after follow-up data collection. The total duration for each subject is estimated to be approximately 7 days.",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Qi NA Jin, PhD","CONTACT","021-64370045","ruijin@rjh.com.cn",[28],{"facility":29,"status":20,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Ruijin Hospital, Affiliated to Shanghai Jiao Tong University School of Medicine","Shanghai","Shanghai Municipality","200025","China","CN",{"type":36,"coordinates":37},"Point",[38,39],121.45806,31.22222,{"lat":39,"lon":38},[42],{"name":43,"role":24,"phone":25,"phoneExt":20,"email":26},"Qi NA Jin",{"type":45,"investigatorFullName":46,"investigatorTitle":5,"investigatorAffiliation":47,"oldNameTitle":20,"oldOrganization":20},"PRINCIPAL_INVESTIGATOR","Gao Henggan","Ruijin-Hainan Hospital Shanghai Jiao Tong University School Of Medicine","100598121","clinical-study-on-the-safety-and-efficacy-of-a-new-magnetic-navigation-radiofrequency-ablation-catheter-for-rapid-arrhythmia-100598121",false,"NCT07067372","Clinical Study on the Safety and Efficacy of a New Magnetic Navigation Radiofrequency Ablation Catheter for Rapid Arrhythmia","Clinical Study on the Safety and Efficacy of FireMagic™ Magbot Ablation Catheter for Rapid Arrhythmia","Rapid arrhythm","Inclusion Criteria:\n\n* 1\\) Patients aged 18 to 80 years old, with no gender restrictions; 2) Patients clinically diagnosed with paroxysmal atrial fibrillation or symptomatic supraventricular tachycardia: i. For patients with paroxysmal atrial fibrillation, atrial fibrillation was recorded by surface electrocardiogram or Holter monitoring (including single-lead electrocardiogram) within one year prior to enrolment; ii. For patients with symptomatic supraventricular tachycardia, PSVT (AVNRT or AVRT) was recorded by electrocardiogram, Holter monitoring, or electrophysiological examination; 3) Patients who have not responded adequately to or are intolerant of at least one antiarrhythmic drug, or who are willing to undergo ablation surgery without prior medication; 4) Patients who fully understand the treatment plan, voluntarily sign the informed consent form, and are willing to undergo the examinations, surgery, and follow-up required by the plan.\n\nExclusion Criteria:\n\n* 1\\) Left atrial thrombus (not applicable for PSVT); 2) Left atrial anteroposterior diameter ≥55 mm (not applicable for PSVT); 3) Left ventricular ejection fraction (LVEF) ≤40%; 4) Previous history of atrial septal defect repair or atrial myxoma (not applicable for PSVT); 5) Presence of active implantable devices (e.g., pacemaker, ICD, etc.); 6) NYHA functional class III-IV; 7) History of cerebrovascular disease within the past 6 months (including cerebral haemorrhage, stroke, transient ischaemic attack); 8) History of cardiovascular events within the past 3 months (including acute myocardial infarction, coronary artery intervention or bypass surgery, artificial valve replacement or repair, atrial or ventricular incision); 9) Acute or severe systemic infection; 10) Patients with severe liver or kidney disease, malignant tumours, or end-stage diseases, or those whom the investigator believes may interfere with the treatment, evaluation, or compliance of this trial; 11) Patients with a significant tendency to bleed, hypercoagulable states, or severe haematological disorders.","ALL","18 Years","80 Years",{"count":60,"type":61},20,"ESTIMATED","INTERVENTIONAL",[64],"NA","Clinical study on the safety and efficacy of FireMagic™ Magbot Ablation Catheter for rapid arrhythmia",[67,68,69],"Rapid Arrhythmia","PFA","Symptomatic Supraventricular Tachycardia",[71,72],"Paroxysmal atrial fibrillation","Symptomatic supraventricular tachycardia","NOT_YET_RECRUITING","2025-07-14",{"date":76,"type":77},"2025-07-16","ACTUAL",{"date":79,"type":61},"2025-12-31",{"date":81,"type":61},"2028-12-31",{"name":5,"class":6},1]